EUVIMEDEUVIMED entdecken
Crossref

Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites

Chiharu Uchiyama, Taichi Terai, Minako Nagai, Kota Nakamura, Yuichiro Kohara, Satoshi Yasuda, Yasuko Matsuo, Shunsuke Doi, Takeshi Sakata, Masayuki Sho

Pancreatology · 2024

DOI: 10.1016/j.pan.2024.07.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pancreatology, 2024. Verfasst von Chiharu Uchiyama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Ascites, Palliative Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The management of malignant ascites is critical for treating patients with advanced pancreatic cancer. The purpose of this study was to assess the safety of cell-free and concentrated ascites reinfusion therapy (CART) and its impact on the prognosis of patients with advanced pancreatic cancer who have massive malignant ascites. METHODS: This study analyzed 47 procedures in 29 patients who underwent CART for ascites caused by pancreatic cancer between 2015 and 2022. Among them, 7 patients who received chemotherapy following CART were classified as the chemotherapy group, while 22 patients without chemotherapy after CART were classified as the palliative care group. RESULTS: Among the 47 procedures, adverse events (AEs) were observed in 9 procedures (19 %). Grade 2 adverse events were observed only in one procedure, manifested as fever. There were no grade 3 or 4 AEs, nor were there any treatment-related deaths. The median survival time was 4.0 months in the chemotherapy group and 0.7 months in the palliative care group (p = 0.004). The albumin level in the chemotherapy group was significantly higher than that in the palliative care group. CONCLUSION: CART is feasible and might be the optimal option to enable prolonged use of chemotherapy to improve the prognosis for late-stage pancreatic cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAscitesPalliative CareHumansMaleFemaleAgedMiddle AgedFeasibility StudiesTreatment OutcomeAged, 80 and overAdultRetrospective StudiesPrognosisAntineoplastic Agents

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
  • Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. Electronic address: m-sho@naramed-u.ac.jp.

Zitieren

APA

Uchiyama, C., Terai, T., Nagai, M., Nakamura, K., Kohara, Y., Yasuda, S., Matsuo, Y., Doi, S., Sakata, T., & Sho, M. (2024). Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Pancreatology. https://doi.org/10.1016/j.pan.2024.07.013

Vancouver

Uchiyama C, Terai T, Nagai M, Nakamura K, Kohara Y, Yasuda S, et al. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Pancreatology. 2024. doi:10.1016/j.pan.2024.07.013

BibTeX
@article{Uchiyama2024,
  author = {Uchiyama, Chiharu and Terai, Taichi and Nagai, Minako and Nakamura, Kota and Kohara, Yuichiro and Yasuda, Satoshi and Matsuo, Yasuko and Doi, Shunsuke and Sakata, Takeshi and Sho, Masayuki},
  title = {Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites},
  journal = {Pancreatology},
  year = {2024},
  doi = {10.1016/j.pan.2024.07.013}
}
Kostenlos starten →